Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
4 Analysts Assess BeiGene: What You Need To Know ↗
 
Via Benzinga
News headline image
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
News headline image
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday. 
Via Benzinga
Topics Stocks
News headline image
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer ↗
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with... 
Via Benzinga
News headline image
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
News headline image
Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
News headline image
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
News headline image
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon ↗
This development comes at a time when the city is grappling with a declining market. 
Via Benzinga
News headline image
Get Rich Quick With These 3 Biotech Stocks to Buy Now ↗
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy. 
Via InvestorPlace
News headline image
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
News headline image
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point ↗
BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target. 
Via Benzinga
News headline image
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
News headline image
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments. 
Via Benzinga
News headline image
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
News headline image
HBM Gets Health Boost From Drug Licensing Deals ↗
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05... 
Via Benzinga
News headline image
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem ↗
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... 
Via Talk Markets
News headline image
7 Biotech Stocks to Buy for Big-Time Gains ↗
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research. 
Via InvestorPlace
News headline image
Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
News headline image
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
News headline image
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin... 
Via Talk Markets
News headline image
BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data ↗
BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR)  
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
News headline image
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. 
Via Benzinga
News headline image
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact ↗
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS). 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.